Was macht Erfahrungen in der Therapie mit Ribonucleinsäuren (RNA) reproduzierbar?

Abstract: In the field of organotherapy there exist clinical studies (Mostly double-blind studies) e. g. for spleen and thymus preparations. From the aspect of indications there exist for example studies in the field of locomotor apparattus, adjuvant tumor therapy, climacterium, Parkinson's disease and chronic tinnitus. The results of such studies are the more heterogenous, the homogenous the patients in these studies are with respect to etiology, age, duration of the diseases and for example accompanying illnesses. For basic reasons, patients with certain accompanying illnesses are generally excluded.Organotherapy in the narrow sense as an organ-specific therapy is mainly used in the case of degenerative diseases of older patients, who often suffer from (accompanying) illness, which are exclusion criteria for clinical studies. These accompanying illnesses are treated as well in organotherapy from a holistic aspect, in order to produce an effect on the main illness as favorable as possible. This is the principle of the individualized holistic therapy.Therapy courses of this kind can be documented via casuistics. In order to secure the comparability of casuistics, uniform parameters have to be used for documentation. That this is often not the case, is shown by a comparison of different casuistics of the therapy of kidney diseases with ribonucleic acids (RNA). An other important aspect of the individual therapy is the adaptation of the therapy to the current disease situation of the patient during a longer period of treatment. This is shown in detail with the help of three case reports of therapies with RNA:- female patient (age 41) with corpus luteum insufficiency- female patient (age 50) with Sjörgen's,syndrome- male patient (age 67) with pseudohemophilia Willebrand-Jürgens syndrome).

Keyword(s): Ribonucleinsäuren

Zurück | Weiter